Fed. Circ. OKs Novartis Loss In Eye Syringe Patent Feud

By Adam Lidgett · September 23, 2024, 6:24 PM EDT

The Federal Circuit has backed a Patent Trial and Appeal Board finding that more than two dozen claims in a Novartis pre-filled eye injection syringe patent weren't patentable....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

-

Date Filed

January 05, 2023

Recent Articles By Adam

July 11, 2024
Senate Clears Patent Bill Aiming To Lower Drug Prices
June 07, 2024
DC Circ. Undoes Library Of Congress Win In Fair Use Fight
June 06, 2024
8th Circ. Affirms Cigna Noncompete Applies To CVS Hire
May 29, 2024
Greenberg Traurig Adds IP Atty From Eversheds Sutherland
May 20, 2024
Judge Tosses Acuitas' COVID Biotech IP Suit
April 30, 2024
FTC Continues To Target 'Junk' Drug Patents
April 10, 2024
Pharmacy Gets Eli Lilly's Mounjaro Suit Tossed
April 09, 2024
Endo Sues FDA Over Generic Adrenalin Approvals
March 25, 2024
Vidal Vacates Denials Of Challenges To Neo Wireless IP
March 21, 2024
Business Coalition Rebuffs Biden Plan To Seize Drug Patents